MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
cbdMD Long-Term Debt 2011-2026 | YCBD
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt cbdMD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.4 M | 125 K | 109 K | 602 K | - | - | 360 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 109 K | 720 K |
Quarterly Long-Term Debt cbdMD
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 201 K | 400 K | 592 K | - | 1.58 M | 1.82 M | - | 2.4 M | 819 | - | - | 125 K | 128 K | 77.7 K | 93.5 K | 109 K | 124 K | 109 K | 5.69 M | 264 K | 6.01 M | 6.01 M | 6.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.91 M | 819 | 1.72 M |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
16.7 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Evoke Pharma
EVOK
|
5 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
4.27 M | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
146 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
39.9 K | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
250 M | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
65 K | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
295 M | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
446 M | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
ProPhase Labs
PRPH
|
2.4 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
38.5 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
21.9 B | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
718 K | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
8.29 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Perrigo Company plc
PRGO
|
3.6 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
Sundial Growers
SNDL
|
16.2 M | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
6.53 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Veru
VERU
|
2.92 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
18 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Pacira BioSciences
PCRX
|
585 M | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
2.58 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
1.23 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
221 M | $ 7.33 | -0.48 % | $ 4.53 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
120 K | - | - | $ 55.5 M | USA |